Significance of WT1 mRNA in the clinical course of lower-risk myelodysplastic syndromes.

Significance of WT1 mRNA in the clinical course of lower-risk myelodysplastic syndromes. - Significance of WT1 mRNA in the clinical course of lower-risk myelodysplastic syndromes.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017862

Enrollment

100

Registered

2015-06-15

Start date

2014-05-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lower-risk myelodysplastic syndromes

Interventions

blood collection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were diagnosed with MDS or ICUS, and meets the categories below; 1: classified as RCUD, RCMD, MDS-U or ICUS 2: more than 20 years old 3: from whom we can obtain documented informed consent.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Impacts of the value of WT1 mRNA on 2 year overall survival	—

Countries

Japan

Contacts

Public ContactTakahiro Suzuki

Jichi Medical University Division of Hematology, Department of Medicine

tasuzuki@jichi.ac.jp0285-58-7353

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026